Stockreport

BRIEF-Dermira Says Initiation Of First Phase 3 Clinical Study In Lebrikizumab Phase 3 Development Program Triggers A $7.5 Mln Milestone Payment By Almirall [Reuters]

Journey Medical Corporation  (DERM) 
Last journey medical corporation earnings: 11/5 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.dermira.com
PDF BRIEF-Dermira Says Initiation Of First Phase 3 Clinical Study In Lebrikizumab Phase 3 Development Program Triggers A $7.5 Mln Milestone Payment By Almirall - Reuters 1 M [Read more]